자료유형 | 학위논문 |
---|---|
서명/저자사항 | Impact of Drug Shortages on Patient Treatment and Survival: The Case of Cytarabine and AML Leukemia. |
개인저자 | Hedlund, Nancy. |
단체저자명 | University of Illinois at Chicago. Health Policy and Administration. |
발행사항 | [S.l.]: University of Illinois at Chicago., 2017. |
발행사항 | Ann Arbor: ProQuest Dissertations & Theses, 2017. |
형태사항 | 351 p. |
기본자료 저록 | Dissertation Abstracts International 79-05B(E). Dissertation Abstract International |
ISBN | 9780355460339 |
학위논문주기 | Thesis (Ph.D.)--University of Illinois at Chicago, 2017. |
일반주기 |
Source: Dissertation Abstracts International, Volume: 79-05(E), Section: B.
Adviser: Lisa Powell. |
이용제한사항 | This item is not available from ProQuest Dissertations & Theses. |
요약 | Introduction: Drug shortages of parenteral injectable medications reached an all time high in calendar year 2011. The focus of this research is to understand implications of a shortage of the chemotherapy drug cytarabine, for which there is no |
요약 | Methods: The study population is patients presenting with an Acute Myelogenous Leukemia diagnosis (AML) between December 2010 and October 2011, during which the FDA determined the cytarabine drug supply to be compromised. Primary data sources w |
요약 | Results: Odds for receipt of treatment within 14 days of diagnosis for persons diagnosed during a period of major shortage was reduced by almost 50% (OR=0.537, p < 0.05). Median days to first qualifying dose inpatient chemotherapy jumped from 7 |
요약 | Conclusion: Diagnosis during a period of major shortage was associated with reduced probability and prolonged time to treatment and a higher hazard for early death. Further study of imbalance between current market price and pharmaceutical manu |
일반주제명 | Public health. Economics. Medicine. |
언어 | 영어 |
바로가기 |
: 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |